Immunic, Inc.
IMUX
$0.8552
$0.00620.73%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.71M | 5.29M | 4.01M | 4.36M | 4.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.08M | 26.83M | 25.63M | 25.73M | 22.81M |
| Operating Income | -27.08M | -26.83M | -25.63M | -25.73M | -22.81M |
| Income Before Tax | -26.82M | -25.47M | -25.18M | -24.37M | -21.38M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.82M | -25.47M | -25.18M | -24.37M | -21.38M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.82M | -25.47M | -25.18M | -24.37M | -21.38M |
| EBIT | -27.08M | -26.83M | -25.63M | -25.73M | -22.81M |
| EBITDA | -27.04M | -26.78M | -25.60M | -25.68M | -22.78M |
| EPS Basic | -0.20 | -0.25 | -0.25 | -0.24 | -0.21 |
| Normalized Basic EPS | -0.13 | -0.15 | -0.16 | -0.15 | -0.13 |
| EPS Diluted | -0.20 | -0.25 | -0.25 | -0.24 | -0.21 |
| Normalized Diluted EPS | -0.13 | -0.15 | -0.16 | -0.15 | -0.13 |
| Average Basic Shares Outstanding | 132.18M | 101.34M | 100.70M | 101.27M | 101.27M |
| Average Diluted Shares Outstanding | 132.18M | 101.34M | 100.70M | 101.27M | 101.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |